Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PPID | Q08752 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31362647 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1GAAKMT2ALMNA | |
| SCHEMBL18640955 | 0.84 | CYP1A2 (0.40) | SMN1; SMN2MEN1GAAKMT2ALMNA | |
| SCHEMBL29488888 | 0.84 | FPR2 (0.33) | GAAALDH1A1KDM4EHPGD | |
| SCHEMBL20142638 | 0.83 | ALDH1A1 (0.46) | SMN1; SMN2MEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL25235485 | 0.82 | KCNB1 (0.34) | LMNAALDH1A1CYP1A2PPIDCYP2C19 | |
| SCHEMBL4196483 | 0.82 | CXCR1 (0.35) | MEN1GAAKMT2ALMNACYP1A2 | |
| SCHEMBL30671308 | 0.82 | MAPT (0.38) | SMN1; SMN2MEN1GAAKMT2ALMNA | |
| SCHEMBL22763608 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1GAAKMT2ALMNA | |
| SCHEMBL18640966 | 0.80 | PPID (0.39) | MEN1GAAKMT2ALMNAKCNA5 | |
| SCHEMBL29214486 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1GAAKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122956-A1 | COMBINATION THERAPY | VIVACE THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025034563-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | VIVACE THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| EP-3956033-B1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12103902-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-114072207-B | Bicyclic compounds | 维瓦斯治疗公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20220298102-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20220298102-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-11420935-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-11384049-B2 | — | — | 2022-07-12 | — | — | US | disclosed |
| US-11384049-B2 | — | — | 2022-07-12 | — | — | US | disclosed |
| EP-3956033-A1 | BICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3877356-A1 | BICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20200347009-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200347009-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020214734-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20180237441-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-08-23 | — | — | US | disclosed |
| EP-3350185-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298102-A1 | BICYCLIC COMPOUNDS | YAP1, TEAD2, TEAD3 | SMN1; SMN2 3337/4885MEN1 2739/4885GAA 3175/4885 |
| US-12103902-B2 | Bicyclic compounds | YAP1, TEAD2, TEAD3 | SMN1; SMN2 3076/4885MEN1 3535/4885GAA 3686/4885 |
| US-11384049-B2 | — | YAP1, HRAS, TFEB | SMN1; SMN2 2955/4885MEN1 2503/4885GAA 1817/4885 |
| US-20180237441-A1 | Chemical Compounds | PSEN1, IRS1, CPT1A | SMN1; SMN2 51/4885MEN1 1729/4885GAA 3733/4885 |
| US-11420935-B2 | Bicyclic compounds | YAP1, TEAD2, TEAD3 | SMN1; SMN2 3337/4885MEN1 2739/4885GAA 3175/4885 |
| US-20200347009-A1 | BICYCLIC COMPOUNDS | YAP1, TEAD2, TEAD3 | SMN1; SMN2 3337/4885MEN1 2739/4885GAA 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.